Xcout Intel
HemostOD
HemostOD is a preclinical-stage biotech company based in Lausanne, Switzerland, pioneering the ex vivo manufacturing of donor-free, off-the-shelf universal human blood platelets to save lives.
Subscribe to see HemostOD’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
HemostOD at a glance
HemostOD is a healthcare biotech company headquartered in Switzerland. It has raised at least $6.5M across the 2 funding rounds on record. Its most recent funding round, Seed, raised $4.7M in October 2025. Xcout tracks 5 named people at HemostOD, including Faouzi Khechana (CEO).
HemostOD leadership
- Faouzi KhechanaCEO
- Elodie DahanCTO
- Laurent MassuyeauExecutive Chairman
- Nicoletta SorvilloCSO
- Thierry NiclouxHead of Operations
HemostOD funding rounds
At least $6.5M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $4.7M | — | |
| Seed | $1.8M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
HemostOD competitors
A few of HemostOD's closest competitors — see the full list of competitors and alternatives →
Cayuga Biotech is a biotechnology company developing novel therapies to address life-threatening hemorrhage by harnessing the body's innate ability to stop bleeding.
Hemoglobin Oxygen Therapeutics LLC develops oxygen-carrying solutions, such as its Hemopure product, for medical applications including organ transplants and preservation. The company serves the healthcare and medical research sectors by providing hemoglobin-based therapeutics used in clinical studies and surgical procedures.
Ferrosa Therapeutics AG is a Swiss biotechnology company founded in Basel, Switzerland, focusing on developing novel therapeutics to treat anemia and related conditions.
Bioxodes is a Belgian clinical-stage biotechnology company founded in 2013 and located in Gosselies. The firm focuses on developing breakthrough treatments for hemorrhagic stroke patients.
Scarlet Therapeutics, founded in 2021 and headquartered in Bristol, United Kingdom, is developing a pioneering platform that generates novel red blood cell-based therapeutics to treat a wide range of diseases.
ATLyphe is a Swiss biotechnology spin-off from ETH Zurich and the University of Zurich founded in 2023 and based in Zürich. The company develops antibody-based solutions engaging T cells for precision immunotherapy, with a focus on improving hematopoietic stem cell transplantation conditioning methods.
Get HemostOD's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on HemostOD in Xcout Intel
- 5 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access